Scienture Holdings, Inc. Reports Q1 2026 Financial Results and Business Update

Scienture Holdings, Inc. announced its financial results for the first quarter ending March 31, 2026. The company reported a significant increase in revenue, which grew by approximately 449% year-over-year to $56 thousand, compared to $10 thousand in the same period last year. This growth was primarily attributed to incremental product orders for ArbliTM. Gross profit also saw a substantial increase of approximately 7900%, rising to $54 thousand from $673 in Q1 2025, with a corresponding expansion in gross margin to 95.6% from 6.6%. The company also highlighted key operational achievements, including the granting of a third patent for ArbliTM, receipt of an Orange Book-listable patent for REZENOPYTM, and the formalization of commercial GPO agreements for REZENOPYTM. Furthermore, Scienture secured $11.0 million in non-dilutive debt financing to support product portfolio growth and R&D pipeline advancement. Despite the revenue growth, the company reported a net loss of approximately $3.4 million for the quarter, compared to a net loss of approximately $3.1 million in the prior-year period. Operating expenses remained relatively stable year-over-year.